Stay current with the latest developments in biotech by subscribing to the newsletter. Novo is conducting trials on its GLP-1 drugs for various indications, including alcohol-related liver disease. Senator Durbin criticizes Amgen for selling a high dose of a lung cancer drug at a significant cost. Eisai and Biogen have applied to sell their Alzheimer’s drug through an autoinjector for maintenance dosing. Different companies offer contrasting views on the heart benefits of Wegovy, with Novo emphasizing weight loss-independent effects and Lilly focusing on weight loss. Stay informed on these developments for a comprehensive understanding of the biotech industry.
Source link
Raw milk, Wegovy tests, Eisai and Biogen
